Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors - Trial NCT06082960
Access comprehensive clinical trial information for NCT06082960 through Pure Global AI's free database. This Phase 1 trial is sponsored by Gilead Sciences and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gilead Sciences
Timeline & Enrollment
Phase 1
Oct 09, 2023
Nov 01, 2026
Primary Outcome
Percentage of Participants With Treatment-emergent Adverse Events,Percentage of Participants With Treatment-emergent Serious Adverse Events,Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs) in Dose-escalation Cohorts
Summary
The main goal of this first in human (FIH) study is to learn about the safety and dosing of
 GS-9911 when given alone or in combination with an anti-programmed cell death protein 1
 (PD-1) monoclonal antibody in participants with advanced solid tumors.
 
 The primary objectives of this study are to:
 
 - Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an
 anti-PD-1 monoclonal antibody in participants with advanced solid tumors
 
 - Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the
 recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with
 an anti-PD-1 monoclonal antibody in participants with advanced solid tumors
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06082960
Non-Device Trial